Pharvaris jumps as skin disease drug meets mid-stage study goal
Pharvaris up after Wedbush initiates stock coverage with 'outperform' rating
Brief: Pharvaris NV Files For Offering Of Up To 6.95 Mln Ordinary Shares By Selling Securityholders
Brief: Pharvaris N.V. reports Q2 EPS EUR -0.63
Pharvaris up as FDA lifts hold on skin disease drug study
Brief: Pharvaris NV Reports Quarterly Basic And Diluted Loss Per Share Of EUR 0.67
Brief: Pharvaris Says Deucrictibant Data Highlighted In Multiple Presentations At C1-Inhibitor Deficiency And Angioedema Workshop
Pharvaris NV expected to post a loss of 74 cents a share - Earnings Preview
Pharvaris falls as Q4 loss widens
Brief: Pharvaris Reports Fourth Quarter Financial Results
Brief: Pharvaris Says Positive Phase 2 Data From Rapide-1 Study Of Phvs416 For On-Demand Treatment Of HAE Attacks Highlighted At 2023 HAEi Regional Conference Apac
Brief: Pharvaris To Highlight Positive Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of HAE Attacks At AAAAI Annual Meeting
Brief: Pharvaris Provides Clinical And Corporate Updates
U.S. STOCKS ON THE MOVE-Regenxbio, Hello Group, copper miners
Pharvaris soars as drug meets goals in mid-stage study
U.S. STOCKS ON THE MOVE-Express, Hershey, Entrada Therapeutics
U.S. STOCKS ON THE MOVE-Rent the Runway, Pharvaris, U.S. energy firms
Brief: Pharvaris Announces Positive Top-Line Phase 2 Data From RAPIDe-1 Study Of PHVS416 For The On-Demand Treatment Of HAE Attacks
Brief: Pharvaris Reports Third Quarter 2022 Financial Results And Provides Business Update